<DOC>
	<DOCNO>NCT02536469</DOCNO>
	<brief_summary>A phase Ib , dose escalation , multiple dose trial HuMax-IL8 patient metastatic unresectable , locally advanced malignant solid tumor .</brief_summary>
	<brief_title>HuMax-IL8 ( Interleukin8 ) Patients With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description>All human subject diagnosis incurable solid tumor eligible dose-escalation phase study . This study consist two phase , dose-escalation phase expansion phase . Subjects treat study treatment off-treatment criterion meet . The safety efficacy assessed end treatment maximum 52 week . In addition , separate visit perform time disease progression patient progression end treatment 52 week . The patient follow overall survival study closure . The study close enrolled patient follow least 52 week die .</detailed_description>
	<criteria>Subjects must metastatic unresectable locally advanced malignant solid tumor . Patients may measurable nonmeasurable evaluable disease . Patients surgically resect metastatic disease high risk relapse also eligible . Patients must complete disease progression least one prior line diseaseappropriate therapy metastatic disease , candidate therapy proven efficacy disease . Patients must recover ( grade 1 baseline ) clinically significant toxicity associate prior therapy Age ≥ 18 year . . ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 1 ( Karnofsky ≥ 70 % ) . Patients must normal organ hematologic function therapy Patients must baseline pulse oximetry &gt; 90 % room air Pregnant woman woman presently breastfeed Concurrent treatment cancer Chronic hepatitis B C infection . Any significant disease , opinion investigator , may impair patient 's tolerance study treatment . Significant dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent . Active autoimmune disease require treatment history autoimmune disease . Concurrent use systemic steroid Patients receive investigational agent Patients untreated central nervous system metastases local treatment brain metastasis History allergic reaction attribute compound similar chemical biologic composition agent use study . Serious uncontrolled intercurrent illness HIVpositive patient ineligible Patients unwilling use adequate contraception Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>